[Strong as death or how efferocytotic macrophages promote the resolution of inflammation].

« Fort comme la mort »,* où comment l’efferocytose contrôle la résolution de l’inflammation.

Publisher: EDK Country of Publication: France NLM ID: 8710980 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1958-5381 (Electronic) Linking ISSN: 07670974 NLM ISO Abbreviation: Med Sci (Paris) Subsets: MEDLINE

Publication: <2003->: Paris : EDK
Original Publication: [Paris] : Flammarion, [1985-

Macrophages*/immunology ; Macrophages*/physiology ; Inflammation*/pathology ; Phagocytosis*/physiology ; Apoptosis*/physiology; Humans ; Animals

The resolution of inflammation is an active process leading to the restoration of tissue homeostasis. A critical step in the initiation of this process is the elimination of apoptotic immune cells by macrophages. This well-organized process, called efferocytosis, involves four different steps, namely the attraction of macrophages to the site where the cells die, the recognition of apoptotic cells, their internalization and their digestion leading to the activation of different metabolic pathways. All these steps are responsible for the reprogramming of macrophages towards a pro-resolving profile. Efferocytic macrophages produce several factors involved in the resolution of inflammation. These factors include lipids (i.e., specialized pro-resolving mediators such as lipoxins), and proteins (e.g., IL-10 or TGF-β). Here, we describe the different steps of efferocytosis and the mechanisms responsible for both macrophage reprogramming and the release of pro-resolving factors. These factors may represent a new therapeutic approach, called resolution therapy.
(© 2024 médecine/sciences – Inserm.)

Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2017 ; 9 : 7204–7218.
Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol 2015 ; 15 : 335–349.
Daguindau E, Chagué C, Saas P. Maladie du greffon contre l’hôte - Les bienfaits du « bon » cholestérol. Med Sci (Paris) 2023; 39 : 418–21.
Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013 ; 13 : 159–175.
Granger V, de Chaisemartin L, Chollet-Martin S. La pêche miraculeuse des filets du neutrophile. Med Sci (Paris) 2014 ; 30 : 544–549.
Watanabe S, Alexander M, Misharin AV, et al. The role of macrophages in the resolution of inflammation. J Clin Invest 2019 ; 129 : 2619–2628.
Delamarre L, Pack M, Chang H, et al. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005 ; 307 : 1630–1634.
Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol 2015 ; 16 : 907–917.
Cabon L, Martinez-Torres A-C, Susin SA. La mort cellulaire programmée ne manque pas de vocabulaire. Med Sci (Paris) 2013 ; 29 : 1117–1124.
Rongvaux A, Jackson R, Harman CCD, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell 2014 ; 159 : 1563–1577.
White MJ, McArthur K, Metcalf D, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 2014 ; 159 : 1549–1562.
Savill JS, Wyllie AH, Henson JE, et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989 ; 83 : 865–875.
Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature 1997 ; 390 : 350–351.
Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998 ; 101 : 890–898.
Bittencourt MC, Perruche S, Contassot E, et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 2001 ; 98 : 224–230.
Golpon HA, Fadok VA, Taraseviciene-Stewart L, et al. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J 2004 ; 18 : 1716–1718.
Green DR, Oguin TH, Martinez J. The clearance of dying cells: table for two. Cell Death Differ 2016 ; 23 : 915–926.
Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008 ; 8 : 279–289.
Saas P, Vetter M, Maraux M, et al. Resolution therapy: Harnessing efferocytic macrophages to trigger the resolution of inflammation. Front Immunol 2022; 13 : 1021413.
Bournazou I, Pound JD, Duffin R, et al. Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. J Clin Invest 2009 ; 119 : 20–32.
Kawano M, Nagata S. Efferocytosis and autoimmune disease. Int Immunol 2018 ; 30 : 551–558.
Lemke G.. How macrophages deal with death. Nat Rev Immunol 2019 ; 19 : 539–549.
Martin CJ, Peters KN, Behar SM. Macrophages Clean Up: Efferocytosis and Microbial Control. Curr Opin Microbiol 2014 ; 0 : 17–23.
Elliott MR, Koster KM, Murphy PS. Efferocytosis Signaling in the Regulation of Macrophage Inflammatory Responses. J Immunol 2017 ; 198 : 1387–1394.
Savill J, Hogg N, Ren Y, et al. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992 ; 90 : 1513–1522.
Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009 ; 138 : 286–299.
Doran AC, Yurdagul A, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol 2020; 20 : 254–67.
Arif Yurdagul J, Subramanian M, Wang X, et al. Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. Cell metabolism 2020; 31 : 518.
Perretti M, Leroy X, Bland EJ, et al. Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation. Trends Pharmacol Sci 2015 ; 36 : 737–755.
Ariel A, Fredman G, Sun Y-P, et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 2006 ; 7 : 1209–1216.
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014 ; 510 : 92–101.
Perretti M, Cooper D, Dalli J, et al. Immune resolution mechanisms in inflammatory arthritis. Nat Rev Rheumatol 2017 ; 13 : 87–99.
Martin-Rodriguez O, Gauthier T, Bonnefoy F, et al. Pro-Resolving Factors Released by Macrophages After Efferocytosis Promote Mucosal Wound Healing in Inflammatory Bowel Disease. Front Immunol 2021; 12 : 754475.
Nathan C, Ding A. Nonresolving inflammation. Cell 2010 ; 140 : 871–882.
Cohen PL, Caricchio R, Abraham V, et al. Delayed Apoptotic Cell Clearance and Lupus-like Autoimmunity in Mice Lacking the c-mer Membrane Tyrosine Kinase. J Exp Med 2002 ; 196 : 135–140.
Kawane K, Tanaka H, Kitahara Y, et al. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A 2010 ; 107 : 19432–19437.
Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009 ; 9 : 62–70.
Kourtzelis I, Li X, Mitroulis I, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat Immunol 2019 ; 20 : 40–49.
Perruche S, Saas P. « Mort sur ordonnance » ou comment l’anticorps anti-CD3 utilise l’apoptose pour induire la tolérance. Med Sci (Paris) 2009 ; 25 : 325–327.
Bonnefoy F, Gauthier T, Vallion R, et al. Factors Produced by Macrophages Eliminating Apoptotic Cells Demonstrate Pro-Resolutive Properties and Terminate Ongoing Inflammation. Front Immunol 2018 ; 9 : 2586.
Mevorach D, Zuckerman T, Reiner I, et al. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial. Biol Blood Marrow Transplant 2014 ; 20 : 58–65.
Sulciner ML, Serhan CN, Gilligan MM, et al. Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med 2018 ; 215 : 115–140.
Wetzel A, Bonnefoy F, Chagué C, et al. Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells. Front Immunol 2021; 12 : 812171.
Kazama H, Ricci J-E, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008 ; 29 : 21–32.
Medina CB, Mehrotra P, Arandjelovic S, et al. Metabolites released from apoptotic cells act as tissue messengers. Nature 2020; 580 : 130–5.
Saas P, Chagué C, Maraux M, et al. Toward the Characterization of Human Pro-Resolving Macrophages? Front Immunol 2020; 11 : 593300.

ANR-11-LABX-0021-01 Agence Nationanle de la Recherche (ANR)

Local Abstract: [Publisher, French] « Fort comme la mort »,* où comment l’efferocytose contrôle la résolution de l’inflammation. [Publisher, French] L’arrêt de la réponse inflammatoire, ou résolution de l’inflammation, est considéré aujourd’hui comme un processus actif lié à la production (ou à la libération) de composés anti-inflammatoires aussi appelés composés pro-résolutifs. L’évènement permettant d’enclencher la résolution de l’inflammation est l’élimination des cellules immunitaires apoptotiques par les macrophages, un processus nommé efferocytose, dont l’altération est à l’origine de différentes maladies. Dans cette synthèse, nous décrivons les étapes de cette efferocytose et les mécanismes qui en résultent et permettent de stopper l’inflammation. Nous évoquerons également de nouvelles pistes thérapeutiques fondées sur les facteurs pro-résolutifs : la thérapie résolutive.

Date Created: 20240531 Date Completed: 20240531 Latest Revision: 20240614

20240615

10.1051/medsci/2024050

38819278